CanBas Co., Ltd.

Patent Applications and Registrations

Patent applications and USPTO patent grants for CanBas Co., Ltd..The latest application filed is for "peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment".

Company Profile

1.15.12

CanBas Co., Ltd. - Shizuoka JP
CanBas Co., Ltd. - Numazu JP
CanBas Co., Ltd. - Numazu city JP
CanBas Co., Ltd. - Numazu, Shizuoka N/A JP

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
IDO/TDO Inhibitor App 20200239452A1 -	2020-07-30
Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment Grant 10,149,887 - Kawabe Dec	2018-12-11
Peptides And Peptidomimetics In Combination With T Cell Activating And/or Checkpoint Inhibiting Agents For Cancer Treatment App 20170112894 - KAWABE; Takumi	2017-04-27
Nrf2-based Cancer Treatment And Detection Methods And Uses App 20160061841 - MINE; Naoki ; et al.	2016-03-03
Peptides and peptidomimetics in combination uses and treatments for cancer patient subpopulations Grant 9,221,872 - Kawabe , et al. December 29, 2	2015-12-29
Peptides And Peptidomimetics In Combination Uses And Treatments For Cancer Patient Subpopulations App 20150056301 - Kawabe; Takumi ; et al.	2015-02-26
Compounds with anti-cancer activity Grant 8,415,357 - Kawabe , et al. April 9, 2	2013-04-09
Compounds with anti-cancer activity Grant 8,084,454 - Kawabe , et al. December 27, 2	2011-12-27
Compounds With Anti-cancer Activity App 20110092514 - KAWABE; TAKUMI ; et al.	2011-04-21
Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents Grant 7,851,592 - Suganuma , et al. December 14, 2	2010-12-14
Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments Grant 7,652,042 - Kawabe , et al. January 26, 2	2010-01-26
Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments Grant 7,629,364 - Kawabe , et al. December 8, 2	2009-12-08
Compounds That Abrogate Dna Damage Induced Cell Cycle G2 Checkpoint And/or Augment Anti-cancer Activity Of Dna-damaging Treatments App 20080293137 - KAWABE; TAKUMI ; et al.	2008-11-27
Compounds with anti-cancer activity App 20080275057 - Kawabe; Takumi ; et al.	2008-11-06
Compounds That Abrogate Dna Damage Induced Cell Cycle G2 Checkpoint And/or Augment Anti-cancer Activity Of Dna-damaging Treatments App 20080227827 - KAWABE; Takumi ; et al.	2008-09-18
Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments Grant 7,407,985 - Kawabe , et al. August 5, 2	2008-08-05
Sensitivity test to predict efficacy of anti-cancer therapies Grant 7,358,046 - Kawabe , et al. April 15, 2	2008-04-15
Anti-fungal compounds and methods of use Grant 7,125,842 - Kawabe , et al. October 24, 2	2006-10-24
Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments App 20060122269 - Kawabe; Takumi ; et al.	2006-06-08
Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments App 20060084610 - Kawabe; Takumi ; et al.	2006-04-20
Compounds that abrogate DNA-damage-induced cell cycle G2 checkpoint and/or augment the anti-cancer activity of DNA damaging treatments Grant 7,030,111 - Kawabe , et al. April 18, 2	2006-04-18
Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments Grant 6,995,135 - Kawabe , et al. February 7, 2	2006-02-07
Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents Grant 6,881,575 - Suganuma , et al. April 19, 2	2005-04-19
Compositions and methods for inhibiting G2 cell cycle arrest and sensitizing cells to DNA damaging agents App 20050059116 - Suganuma, Masashi ; et al.	2005-03-17
Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments App 20040248783 - Kawabe, Takumi ; et al.	2004-12-09

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.